Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 149Fluorouracil 136Gemcitabine 117Bevacizumab 115Leucovorin 106Specimen Handling 105Capecitabine 95pembrolizumab 89Magnetic Resonance Spectroscopy 83Cisplatin 79Nivolumab 77Irinotecan 71durvalumab 63Cetuximab 62Paclitaxel 60Biopsy 60130-nm albumin-bound paclitaxel 60atezolizumab 44Radiotherapy 44Taxes 36Carboplatin 36Albumin-Bound Paclitaxel 36Folfox protocol 35Drug Therapy 31Cyclophosphamide 30lenvatinib 29dehydroftorafur 28tislelizumab 27sintilimab 27Radiation 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
C188-9 compound × Gastrointestinal × 90 days × Clear all
NCT06141031 2026-05-27

Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

Washington University School of Medicine

Phase 1 Recruiting
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05440708 2026-04-27

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Tvardi Therapeutics, Incorporated

Phase 1/2 Recruiting
193 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡